These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 39245001)

  • 1. The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects.
    Tian S; Wang B; Ding Y; Zhang Y; Yu P; Chang YZ; Gao G
    Biomed Pharmacother; 2024 Oct; 179():117419. PubMed ID: 39245001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain iron metabolism and its perturbation in neurological diseases.
    Crichton RR; Dexter DT; Ward RJ
    J Neural Transm (Vienna); 2011 Mar; 118(3):301-14. PubMed ID: 20809066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer's, and Parkinson's Diseases.
    Raha AA; Biswas A; Henderson J; Chakraborty S; Holland A; Friedland RP; Mukaetova-Ladinska E; Zaman S; Raha-Chowdhury R
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain Iron Metabolism Dysfunction in Parkinson's Disease.
    Jiang H; Wang J; Rogers J; Xie J
    Mol Neurobiol; 2017 May; 54(4):3078-3101. PubMed ID: 27039308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron Homeostasis Disorder and Alzheimer's Disease.
    Peng Y; Chang X; Lang M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
    Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
    Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats.
    Lu LN; Qian ZM; Wu KC; Yung WH; Ke Y
    Mol Neurobiol; 2017 Sep; 54(7):5213-5224. PubMed ID: 27578012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease.
    Goyal A; Verma A; Dubey N; Raghav J; Agrawal A
    J Food Biochem; 2022 Dec; 46(12):e14415. PubMed ID: 36106706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress.
    Thompson K; Menzies S; Muckenthaler M; Torti FM; Wood T; Torti SV; Hentze MW; Beard J; Connor J
    J Neurosci Res; 2003 Jan; 71(1):46-63. PubMed ID: 12478613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.
    Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S
    Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin: Nature's promising warrior against Alzheimer's and Parkinson's disease.
    Goyal A; Solanki K; Verma A
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23619. PubMed ID: 38091364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferroportin1 in the brain.
    Qian ZM; Li W; Guo Q
    Ageing Res Rev; 2023 Jul; 88():101961. PubMed ID: 37236369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects.
    Tong B; Ba Y; Li Z; Yang C; Su K; Qi H; Zhang D; Liu X; Wu Y; Chen Y; Ling J; Zhang J; Yin X; Yu P
    Neurobiol Dis; 2024 Jun; 196():106505. PubMed ID: 38642715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis: A potential therapeutic target for neurodegenerative diseases.
    Vitalakumar D; Sharma A; Flora SJS
    J Biochem Mol Toxicol; 2021 Aug; 35(8):e22830. PubMed ID: 34047408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.